search:cancer drug resistance database相關網頁資料

瀏覽:1234
日期:2024-08-06
Chemotherapy (often abbreviated to chemo and sometimes CTX or CTx) is a category of cancer treatment that uses chemical substances, especially one or more anti-cancer drugs (chemotherapeutic agents) that are given as part of a standardized chemotherapy re...
瀏覽:904
日期:2024-08-05
Cancer therapies are limited by the development of drug resistance, and mutations in drug targets is one of the main reasons for developing acquired resistance. The adequate knowledge of these mutations in drug targets would help to design effective perso...
瀏覽:1271
日期:2024-08-07
Drug Resistance and Molecular Cancer Therapy: Apoptosis Versus Autophagy | InTechOpen, Published on: 2013-05-15. Authors: Rebecca T. Marquez, Bryan W. Tsao, Nicholas F. Faust, et ... Figure 4. Cross-talk between apoptosis and autophagy. Autophagy ......
瀏覽:1271
日期:2024-08-05
Drug resistance is the reduction in effectiveness of a drug such as an antimicrobial, anthelmintic or an antineoplastic[1] in curing a disease or condition. When the drug is not intended to kill or inhibit a pathogen, then the term is equivalent to dosage...
瀏覽:1417
日期:2024-08-04
The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics a...
瀏覽:324
日期:2024-08-04
2.3. Drug Binding in BCRP An earlier study demonstrated that two different substrates such as mitoxantrone and rhodamine 123, topotecan or daunorubicin did not reciprocally inhibit the efflux of each other [58], suggesting that there are multiple drug bin...
瀏覽:1060
日期:2024-08-03
Anticancer Drug Metabolism: Chemotherapy Resistance and New Therapeutic Approaches | InTechOpen, Published on: 2012-02-22. Authors: Hanane Akhdar, Claire Legendre, Caroline Aninat, et ... 2. Anticancer drugs Anticancer or chemotherapy drugs are ......
瀏覽:562
日期:2024-08-08
Abstract Targeted blockade of aberrantly activated signaling pathways is an attractive therapeutic strategy for solid tumors, but drug resistance is common. KRAS is a frequently mutated gene in human cancer but remains a challenging clinical target. Inhib...